REFERENCES
- Callahan EJ, Rawson RA, McCleave B, Arias R, Glazer M, Liberman RP. The treatment of heroin addiction: naltrexone alone and with behavior therapy. The International of the Addictions. 1980;15:795–807. [CSA]
- Kosten T, Kleber HD. Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse. 1984;10:249–266. [PUBMED], [CSA]
- De Leon G, Schwartz S. Therapeutic communities: what are the retention rates? Am J Drug Alcohol Abuse. 1984;10:267–284. [PUBMED], [INFOTRIEVE], [CSA]
- Guydish J, Werdegar D, Sorensen JL, Clark W, Acampora A. A day treatment program in a therapeutic community setting: six-month outcomes. The Walden House Day Treatment Program. J Subst Abuse Treat. 1995;12:441–447. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Keen J, Oliver P, Rowse G, Mathers N. Residential rehabilitation for drug users: a review of thirteen months' intake to a therapeutic community. Fam Pract. 2001;18:545–548. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Greenstein RA, Evans BD, McLellan AT, O'Brien CP. Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend. 1983;12:173–180. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Greenstein RA, Resnick RB, Resnick E. Methadone and naltrexone in the treatment of heroin dependence: Symposium on Clinical Psychopharmacology II. Psychiatr Clin North Am. 1984;7:671–679. [PUBMED], [INFOTRIEVE], [CSA]
- Washton AM, Gold MS, Pottash AC. Successful use of naltrexone in addicted physicians and business executives. Advanced Alcohol and Substance Abuse. 1984;4:89–96. [CSA]
- Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur J Clin Invest. 2003;33:824–829. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kirchmayer U, Davoli M, Verster A, Amato L, Feri M, Perucci CA. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction. 2002;97:1241–1249. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Grabowski J, O'Brien C, Greenstein R, Ternes J. Effects of contingent payment on compliance with a naltrexone regimen. Am J Drug Alcohol Abuse. 1979;6:355–365. [PUBMED], [INFOTRIEVE], [CSA]
- Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54:125–137. [CSA]
- Carroll KM, Ball SA, Nich C, , et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58:755–761. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Silverman K, Wong CJ, Higgins ST, , et al. Increasing opiate abstinence through voucher-based reinforcement therapy. Drug Alcohol Depend. 1996;41:157–165. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Higgins ST, Alessi SM, Dantona RL. Voucher-based incentives: a substance abuse treatment innovation. Addict Behav. 2002;27:887–910. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rothenberg JL, Sullivan MA, Church SH, , et al. Behavioral naltrexone therapy: an integrated therapy for opiate dependence. J Subst Abuse Treat. 2002;23:351–360. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Collins ED, Whittington RA, Heitler NE, Kleber HD. A randomized comparison of anesthesia-assisted heroin detoxification with buprenorphine- and clonidine-assisted detoxifications. Presentation at College on Problems of Drug Dependence 63rd Annual Scientific Meeting, Scottsdale, Arizona, June 16–21, 2001.
- O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting: a randomized trial. Ann Intern Med. 1997;127:526–530. [PUBMED], [INFOTRIEVE], [CSA]
- Kosten T, Morgan C, Kleber HD. Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. NIDA Res Monogr. 1992;121:101–119. [PUBMED], [INFOTRIEVE], [CSA]
- Stine SM, Kosten TR. Use of drug combinations in treatment of opioid withdrawal. J Clin Psychopharmacol. 1992;12:203–209. [PUBMED], [INFOTRIEVE], [CSA]
- Hunt GM, Azrin NH. A community reinforcement approach to alcoholism. Behav Res Ther. 1973;11:91–104. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Galanter M. Network therapy for addiction: a model for office practice. Am J Psychiatry. 1993;150(1):28–36. [PUBMED], [INFOTRIEVE], [CSA]
- Galanter M, Keller DS, Dermatis H. Network therapy for addiction: assessment of the clinical outcome of training. Am J Drug Alcohol Abuse. 1997;23:355–367. [PUBMED], [INFOTRIEVE], [CSA]
- Meyers R, Smith J. The community reinforcement approach. In: Reid HK, Miller W, eds. Handbook of Alcoholism Treatment Approaches Effective Alternatives. 2nd ed. Boston, MA: Allyn and Bacon; 1995.
- O'Connor PG, Waugh ME, Schottenfeld RS, Diakongiannis IA, Rounsaville BJ. Ambulatory opiate detoxification and primary care: a role for the primary care physician. J Gen Intern Med. 1992;7:532–534. [PUBMED], [INFOTRIEVE], [CSA]
- Dubbert PM, King A, Rapp S, Brief D, Martin JE, Lake M. Riboflavin as a tracer of medication compliance. J Behav Med. 1985;8:287–299. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res. 1996;20:1412–1417. [PUBMED], [INFOTRIEVE], [CSA]
- McLellan AT, Kushner H, Metzger D, , et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199–213. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sobell MB, Maisto SA, Sobell LC, Cooper AM, Cooper T, Sanders B. Developing a prototype for evaluating treatment effectiveness. In: Sobell LC, Sobell MD, Ward E, eds. Evaluating Alcohol and Drug Abuse Treatment Effectiveness: Recent Advances. New York: Pergamon Press, 1980;129–150.
- Montogomery HA, Miller WR, Tonigan JS, Hester RK, Abbot PJ, Delaney HD. SOCRATES as presage: validation of a new instrument for assessing motivation for behavior change in problem drinkers. Paper presented at annual meeting of the Association for Advancement of Behavior Therapy, San Francisco, Colif., November, 1990.
- Charney DS, Heninger G, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry. 1986;143:831–837. [PUBMED], [INFOTRIEVE], [CSA]
- Resnick RB, Washton AM. Clinical outcome with naltrexone: predictor variables and follow-up status in detoxified heroin addicts. Ann N Y Acad Sci. 1978;311:241–246. [PUBMED], [INFOTRIEVE], [CSA]
- Carroll KM, Power M-ED, Bryant K, Rounsaville BJ. One-year follow-up status of treatment-seeking cocaine abusers: psychopathology and dependence severity as predictors of outcome. J Nerv Ment Dis. 1993;181:71–79. [PUBMED], [INFOTRIEVE], [CSA]
- Brewer DD, Catalano RF, Haggerty K, Gainey RR, Fleming CB. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998;93:73–92. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kutz I, Reznik V. Rapid heroin detoxification using a single high dose of buprenorphine. J Psychoactive Drugs. 2001;33:191–193. [PUBMED], [INFOTRIEVE], [CSA]
- Umbricht A, Montoya ID, Hoover DR, Demuth KL, Chiang CT, Preston KL. Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend. 1999;56:181–190. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Aceto MD. Characterization of prototypical opioid antagonists, agonist-antagonists, and agonists in the morphine-dependent rhesus monkey. Neuropeptides. 1984;5:1–3, 15–18. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Stitzer ML, Iguchi MY, Kidorf M, Bigelow GE. Contingency management in methadone treatment: the case for positive incentives. NIDA Res Monogr. 1993;137:19–36. [PUBMED], [INFOTRIEVE], [CSA]
- Higgins ST, Delaney DD, Budney AJ, , et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry. 1991;148(9):1218–1224. [PUBMED], [INFOTRIEVE], [CSA]
- Higgins ST, Petry NM. Contingency management: incentives for sobriety. Alcohol Res Health. 1999;23:122–127. [PUBMED], [INFOTRIEVE], [CSA]
- Budney AJ, Higgins SY, Delaney DD, Kent L, Bickel WK. Contingent reinforcement of abstinence with individuals abusing cocaine and marijuana. J Appl Behav Anal. 1991;24:657–665. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rounsaville BJ, Weissman MM, Crits-Christoph K, Wilber C, Kleber HD. Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39:151–156. [PUBMED], [INFOTRIEVE], [CSA]
- Rounsaville BJ, Kosten TR, Weissman MM, Kleber HD. Prognostic significance of psychopathology in treated opiate addicts: a 2.5-year follow-up study. Arch Gen Psychiatry. 1986;43:739–745. [PUBMED], [INFOTRIEVE], [CSA]
- Kokkevi A, Stefanis N, Anastasopoulou E, Kostogianni C. Personality disorders in drug abusers: prevalence and their association with Axis I disorders as predictors of treatment retention. Addict Behav. 1998;23:841–853. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nunes EV, Quitkin FM, Donovan S, , et al. Imipramine treatment of opiate dependent patients with depressive disorders: a placebo-controlled trial. Arch Gen Psychiatry. 1998;55:153–160. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hamilton S, Nunes E, Klimchak C. Treatment of depressed methadone maintenance patients with nefazodone: a case series. Am J Addict. 1998;7:309–312. [PUBMED], [INFOTRIEVE], [CSA]
- Nunes EV, Quitkin FM, Brady R, Koenig T. Antidepressant treatment in methadone maintenance patients. J Addict Dis. 1994;13:13–24. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Woody GE, O'Brien BP, Rickels K. Depression and anxiety in heroin addicts: a placebo controlled study of doxepin in combination with methadone. Am J Psychiatry. 1975;132:447–450. [PUBMED], [INFOTRIEVE], [CSA]
- Gerra G, Fertonani G, Zaimovic A, , et al. Hostility in heroin abusers subtypes: fluoxetine and naltrexone treatment. Prog Neuro-Psychopharamacol Biol Psychiatry. 1995;19:1225–1237. [CSA], [CROSSREF]
- Landabaso MA, Iraurgi I, Jimenez-Lerma JM, , et al. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction. 1998;93:739–744. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hitsman B, Mahableshwarkar A, Pingitore R, , et al. Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol. 1999;67:547–554. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hall SM, Reus VI, Munoz RF, , et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry. 1998;55:683–690. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hurt RD, Sachs DPL, Gloner ED, , et al. A comparison of sustained-release bupropion, and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Volpicelli JR, Alterman AI, Hayashida A, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–880. [PUBMED], [INFOTRIEVE], [CSA]
- O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Mayer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881–887. [PUBMED], [INFOTRIEVE], [CSA]
- Mason BJ, Ritvo ED, Morgan RO, , et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18:1162–1167. [PUBMED], [INFOTRIEVE], [CSA]
- Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719–724. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction? NIDA Res Monogr. 1995;150:37–52. [PUBMED], [INFOTRIEVE], [CSA]
- Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse, and survival among opiate addicts after treatment: a prospective follow-up study. Br J Psychiatry. 1989;154:348–353. [PUBMED], [INFOTRIEVE], [CSA]